| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JMOLDX.2013.03.002 |
| P698 | PubMed publication ID | 23672976 |
| P50 | author | Stephen M. Hewitt | Q30361876 |
| P2093 | author name string | Richard A Bender | |
| David B Krizman | |||
| Wei-Li Liao | |||
| Jon Burrows | |||
| Sheeno Thyparambil | |||
| Todd Hembrough | |||
| Marlene M Darfler | |||
| Joseph Abdo | |||
| Kathleen M Bengali | |||
| P433 | issue | 4 | |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 454-465 | |
| P577 | publication date | 2013-05-11 | |
| P1433 | published in | The Journal of Molecular Diagnostics | Q7743603 |
| P1476 | title | Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffin-embedded tumor tissue. | |
| P478 | volume | 15 |
| Q33830522 | Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue |
| Q48115878 | An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer. |
| Q35048633 | Application of tissue mesodissection to molecular cancer diagnostics |
| Q34693949 | Applications of mass spectrometry for quantitative protein analysis in formalin-fixed paraffin-embedded tissues. |
| Q38543009 | Cancer proteomics: developments in technology, clinical use and commercialization |
| Q64096309 | Clinical potential of mass spectrometry-based proteogenomics |
| Q58554058 | Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer |
| Q34270592 | Establishing ion ratio thresholds based on absolute peak area for absolute protein quantification using protein cleavage isotope dilution mass spectrometry |
| Q93384504 | Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas |
| Q37142882 | High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy. |
| Q31140924 | How may targeted proteomics complement genomic data in breast cancer? |
| Q37682961 | MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. |
| Q35845600 | Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH. |
| Q39146393 | Opportunities and Challenges of Multiplex Assays: A Machine Learning Perspective |
| Q37244491 | Optimized Protocol for Quantitative Multiple Reaction Monitoring-Based Proteomic Analysis of Formalin-Fixed, Paraffin-Embedded Tissues |
| Q47890629 | Protein levels of clusterin and glutathione synthetase in platelets allow for early detection of colorectal cancer. |
| Q38384375 | Proteins from formalin-fixed paraffin-embedded prostate cancer sections that predict the risk of metastatic disease. |
| Q38567805 | Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib |
| Q27015506 | Quantification of HER family receptors in breast cancer |
| Q36134039 | Quantification of HER2 by Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded (FFPE) Breast Cancer Tissues. |
| Q37735589 | Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment |
| Q35714211 | Recent progress in protein profiling of clinical tissues for next-generation molecular diagnostics |
| Q92417231 | Synthetic Antigen Gels as Practical Controls for Standardized and Quantitative Immunohistochemistry |
| Q90183323 | Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer |
| Q38604366 | Targeted proteomics of solid cancers: from quantification of known biomarkers towards reading the digital proteome maps |
| Q49961144 | Targeted therapies for targeted populations: Anti-EGFR treatment for EGFR amplified gastroesophageal adenocarcinoma |
| Q64993592 | Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. |
| Q50854840 | Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance. |
| Q64067557 | Translation and evaluation of a pre-clinical 5-protein response prediction signature in a breast cancer phase Ib clinical trial |
| Q40092107 | Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. |
Search more.